Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.44 |
| ▸ | BCHE | P06276 | 4/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30706180 | 1.00 | HTR6 (0.44) | HTR6BCHEIRAK1ACKR3LCK | |
| SCHEMBL30794025 | 0.96 | PRMT5 (0.42) | HTR6BCHEIRAK1PRMT5JAK2 | |
| SCHEMBL30794352 | 0.96 | PRMT5 (0.42) | HTR6BCHEIRAK1PRMT5JAK2 | |
| SCHEMBL30794350 | 0.96 | PRMT5 (0.42) | HTR6BCHEIRAK1PRMT5JAK2 | |
| SCHEMBL30706001 | 0.94 | HTR6 (0.42) | HTR6BCHEIRAK1USP30PRMT5 | |
| SCHEMBL26925369 | 0.92 | LCK (0.39) | HTR6BCHEIRAK1LCK | |
| SCHEMBL26925376 | 0.92 | LCK (0.39) | HTR6BCHEIRAK1LCK | |
| SCHEMBL30706067 | 0.89 | USP30 (0.44) | HTR6BCHEUSP30PRMT5CCNT1 | |
| SCHEMBL30706104 | 0.89 | USP30 (0.44) | HTR6BCHEUSP30PRMT5CCNT1 | |
| SCHEMBL30705970 | 0.88 | PRMT5 (0.45) | PRMT5JAK2CCNT1CDK9KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | HTR6 3916/4885BCHE 3195/4885IRAK1 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.